Agoracom Blog Home

Posts Tagged ‘small cap’

« Older Entries
Newer Entries »

ImagineAR $IP.ca $IPNFF Supports Chef Claudy Pierre’s for E.A.T. Initiative & 2020 World Food Day Celebration $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 7:09 AM on Wednesday, October 7th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

ImagineAR Supports Chef Claudy Pierre’s for E.A.T. Initiative & 2020 World Food Day Celebration

  • Providing its augmented reality self-service platform to support Chef Claudy Pierre’s E.A.T. Initiative program in partnership with Pittsburgh Gateways’ Energy Innovation Center (EIC) in Pittsburgh, Pennsylvania
  • During this pandemic, Pierre has started providing food to the community from the EIC Kitchen and has donated over 30,000 meals and Blessing Boxes, thanks to the support of the EIC and corporate partners such as Chime Bank and Super Bakery.

VANCOUVER, BC and ERIE, Pa., Oct. 7, 2020 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) is providing its augmented reality self-service platform to support Chef Claudy Pierre’s E.A.T. Initiative program in partnership with Pittsburgh Gateways’ Energy Innovation Center (EIC) in Pittsburgh, Pennsylvania. During this pandemic, Pierre has started providing food to the community from the EIC Kitchen and has donated over 30,000 meals and Blessing Boxes, thanks to the support of the EIC and corporate partners such as Chime Bank and Super Bakery.

“Since the beginning of the pandemic we have been able to serve local residents over 30,000 meals,” said Pierre. “AR provides us an innovative way to tell our EIC story and recognize corporate partners like Chime Bank. ImagineAR technology is really cool, and the community reaction has been overwhelming.”

The ImagineAR program includes using the ImagineAR app to deliver a motivational video message about the program and an interactive 3D AR mascot of Pierre. Recently, recipients of the Blessing Boxes were asked to download the ImagineAR app and scan the Blessing Boxes logo to instantly experience the motivational video on their mobile phone. In addition, the 3D mascot of Pierre will be used for social media programs to extend community awareness.

Neal Bendesky, Vice President of Sales for ImagineAR, said, “We are proud to support the EIC and Chef Claudy for their community outreach program. Chef Claudy’s commitment as a stakeholder in Pittsburgh is the type of leadership that represents necessary strides in our country. We’re excited to utilize his 3D AR image to create social media activations and build the EIC’s AR community.”

The EIC and ImagineAR partnership was recently developed by former 15-year NFL quarterback Gus Frerotte, who houses his media production unit at the EIC. Frerotte, Bendesky and ImagineAR CEO Alen Paul Silverrstieen, along with Robert Meeder, President and CEO of Pittsburgh Gateways Corporation and the EIC, are supporting Pierre’s community outreach as a start to introducing trending technology like AR to support local and regional businesses.

“Chef Claudy is a hometown hero, and we hope other corporations rally around his efforts during these uncharted times,” added Frerotte.

On October 16, 2020, the E.A.T. Initiative will host the 2020 World Food Day Celebration as the City of Pittsburgh’s official acknowledgement of the 75th Anniversary of World Food Day, hosted by the United Nation’s Food & Agriculture Organization.

About Pittsburgh Gateway
Pittsburgh Gateways Corporation’s mission is to provide strategic planning, development and direct management assistance for communities, community-based economic development organizations, research & academic institutions and private entities seeking the acceleration of technology-based businesses. Incorporated into this mission is our goal to combat community deterioration in the City of Pittsburgh and other economically distressed areas of Pennsylvania. Pittsburgh Gateways Corporation is registered as a 501(c)(3) non-profit organization. For more information, visit www.pghgateways.org/.

About ImagineAR

Imagine AR Inc. (CSE: IP) (OTC: IPNFF) has developed ImagineAR.com; an “AR-as-a-Service” platform for desktops that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds using ImagineAR. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage with videos, information, advertisements, coupons, 3D holograms and any interactive content, all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The ImagineAR.com mobile app is available in the IOS and Android mobile app stores. The platform is available as a native mode SDK. For more information or to explore working with ImagineAR, please visit www.imaginear.com.

All trademarks of the property of respective owners.
ON BEHALF OF THE BOARD
Alen Paul Silverrstieen
President & CEO
(818) 850-2490

(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if ImagineAR Entertainment Inc. (CSE: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Featured, Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF Supports Chef Claudy Pierre’s for E.A.T. Initiative & 2020 World Food Day Celebration $SEV.ca $VST.ca $YDX.ca $NTAR.ca

PyroGenesis $PYR.ca Files Application to Uplist to #TSX as a Technology Company $RTN $NOC $UTX $DDD.ca

Posted by AGORACOM-JC at 3:13 PM on Tuesday, October 6th, 2020
  • Announce that it has applied to have its common shares listed on the Toronto Stock Exchange, as a technology Company
  • Upon receiving conditional approval from the TSX, the Company will consider, based on market conditions at the time, if it will proceed in due course
  • In the interim, the Company has, and will, file the appropriate documents and take all other measures to be in position to act quickly should the opportunity to up-list be acceptable to the Board of Directors

MONTREAL, Oct. 06, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products,  is pleased to announce that it has applied to have its common shares listed on the Toronto Stock Exchange (“TSX”), as a technology Company.

Listing is subject to the approval of the TSX in accordance with its original listing requirements for technology companies. The TSX has not conditionally approved the company’s listing application and there is no assurance that the TSX will approve the listing application. Without limitation, the original listing requirements of the TSX provide that a company must have a minimum of $10,000,000 in the treasury, the majority of which has been raised by the issuance of securities qualified for distribution by a prospectus, which requirement is not currently satisfied by the company.

“We are proud to announce today that the Board of Directors of PyroGenesis, believing  that the Company is at a stage where investors could benefit from an up-listing to a more senior exchange, has taken, and is taking, steps to do just that,” said P. Peter Pascali, CEO of PyroGenesis Canada Inc. “Although the Company does not need to raise cash for working capital purposes it does not, as noted, have on its balance sheet the requisite funds raised by prospectus which is mandated by the TSX for any company that wants to be listed as a technology company.  Upon receiving conditional approval from the TSX, the Company will consider, based on market conditions at the time, if it will proceed in due course.  In the interim, the Company has, and will, file the appropriate documents and take all other measures to be in position to act quickly should the opportunity to up-list be acceptable to the Board of Directors. Notwithstanding our sincere desire to up-list, there is no guarantee that either the TSX will approve the listing application or that the market conditions at the time of approval will be acceptable to the Board. Should for any reason the up listing not be pursued, we would consider that a material change which would be press released immediately.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

Tags: , , , , , , , , , ,
Posted in PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Files Application to Uplist to #TSX as a Technology Company $RTN $NOC $UTX $DDD.ca

Else Nutrition $BABY.ca Announces Closing of $20.7 Million Upsized Bought Deal Public Offering and Concurrent $5 million Private Placement $BMY $ABT $TSN $CAG

Posted by AGORACOM-JC at 10:07 AM on Tuesday, October 6th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Closed its previously announced upsized bought deal public offering of units for ‎aggregate gross proceeds of approximately CAD$20.7 million, including the exercise of the over-allotment option in full
  • The Company issued ‎‎9,200,000 Units at a price of CAD$2.25 per Unit, each Unit consisting of one common share of the ‎Company and one-half of one common share purchase warrant, with each whole warrant entitling the holder to purchase one Share at the price of CAD$3.25 per Share until October 6, 2022
  • In total, the Company received gross proceeds of approximately CAD$25.7 million from the closing of the Offering and Private Placement

VANCOUVER, BC / October 6, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), is pleased to announce that it has closed its previously announced upsized bought deal public offering of units (the “Units“) for ‎aggregate gross proceeds of approximately CAD$20.7 million, including the exercise of the over-allotment option in full (the “Offering“). The Company issued ‎‎9,200,000 Units at a price of CAD$2.25 per Unit, each Unit consisting of one common share of the ‎Company (a “Share“) and one-half of one common share purchase warrant, with each whole warrant (a “Warrant“) ‎entitling the holder to purchase one Share at the price of CAD$3.25 per Share until October 6, 2022. ‎The Company has received approval from the TSX Venture Exchange (“TSXV“) to list the Warrants issued pursuant to the Offering, and the Warrants are expected to be listed and posted for trading on the TSXV under the ticker symbol “BABY.WT” effective on or about October 8, 2020.

Concurrent with the Offering, the Company issued 2,224,111 Units on a private placement basis, for additional gross proceeds of approximately CAD$5 million (the “Private Placement“). New H2 Limited (“New H2“), a wholly owned subsidiary of Health and Happiness (H&H) International Holdings Ltd, a Hong Kong Stock Exchange company (HK:1112), subscribed for CAD$4,000,000 worth of Units in the Private Placement pursuant to a previously disclosed investor rights agreement dated March 2, 2020 between the Company and New H2.

In total, the Company received gross proceeds of approximately CAD$25.7 million from the closing of the Offering and Private Placement.

The Offering was conducted on a bought deal basis by Canaccord Genuity Corp. and Haywood ‎Securities Inc. (collectively, the “Underwriters“). On closing, the Company issued to the Underwriters an aggregate ‎of 597,920 broker warrants (the “Broker Warrants“), each Broker Warrant entitling the holder to ‎purchase one Share at the price of CAD$2.25 per Share until October 6, 2022.‎

The Units issued pursuant to the Offering were offered by way of a short form prospectus filed in all provinces of Canada except Quebec and elsewhere on a private placement basis. The Company intends to use the net proceeds of the Offering and the Private Placement for marketing, distribution, inventory and general corporate purposes.

All securities issued in connection with the Private Placement are subject to a four month hold period pursuant to the policies of the TSX Venture Exchange and applicable securities laws.

The securities offered have not been, nor will they be, registered under the U.S Securities Act of 1933 (the “U.S. Securities Act“) or any ‎state securities laws, and may not be offered or sold in the United States or to, or for the account or ‎benefit of, any person in the United States or to U.S. Persons (as such term is defined in Regulation S ‎under the U.S. Securities Act) absent registration or an applicable exemption from the registration ‎requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy ‎nor will there be any sale of the securities in any state in which such offer, solicitation or sale would be ‎unlawful.‎

MI 61-101

New H2’s subscription for Units in the Private Placement constitutes a “related party transaction” within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). The transaction is exempt from the formal valuation requirements of MI 61-101 pursuant to section 5.5(a) and the minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(a) as the fair market value of the related party’s subscription will not be more than 25% of the Company’s market capitalization. The Company will be filing a material change report in respect of the related party transaction on SEDAR less than 21 days prior to the closing of the transaction due to the fact that the Company wished to close the transaction as soon as possible.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed on the TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For additional information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements relating to the trading date of the Warrants and the intended use of the net proceeds of ‎the Offering and the Private Placement. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings

Tags: , , , , , , , , , , ,
Posted in Else Nutrition Holdings Inc., Featured | Comments Off on Else Nutrition $BABY.ca Announces Closing of $20.7 Million Upsized Bought Deal Public Offering and Concurrent $5 million Private Placement $BMY $ABT $TSN $CAG

Hollister Biosciences $HOLL.ca 100% Owned Subsidiary Venom Extracts Achieves Initial $30 Million Revenue Milestone $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:16 AM on Tuesday, October 6th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • On September 23 rd , 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020
  • 100% owned subsidiary, Venom Extracts achieved the first of two revenue milestones in accordance with the terms of the definitive agreement
  • As a result, the Company will issue 19,740,036 common shares to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share

VANCOUVER, BC , Oct. 6, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (Frankfurt: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 230 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce that further to the news release dated March 30 th , 2020, its 100% owned subsidiary, Venom Extracts (” Venom “) has achieved the first of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company (the ” Transaction “).

On September 23 rd , 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020. As a result, the Company will issue 19,740,036 common shares (the ” Earn-Out Shares “) to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.

“We are very pleased with the performance of the Arizona team in their ability to achieve this key milestone so expeditiously,” shared Carl Saling , CEO of Hollister .

None of the securities to be issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the ” U.S. Securities Act “), or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Tags: , , , , , , , , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca 100% Owned Subsidiary Venom Extracts Achieves Initial $30 Million Revenue Milestone $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Empower Clinics $CBDT.ca Acquires Medical Laboratory Capable of Processing 4,000 #COVID-19 RT-PCR Tests Per Day $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:02 AM on Tuesday, October 6th, 2020

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX, will advance Empower COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses, colleges and universities

  • Pursuant to the terms of a membership interest purchase agreement dated October 5, 2020, has completed the acquisition of Kai Medical Laboratory, LLC (“KAI“) from KTM5 Holdings, LLC, NULV11, LLC and Consistent Investment Group, LLC (together, the “Vendors“), through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for consideration having an aggregate value of US$1,971,857 (CAD$2,613,478), effective as of October 5, 2020 (the “Transaction“).

VANCOUVER BC / October 6, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) is pleased to announce that, pursuant to the terms of a membership interest purchase agreement dated October 5, 2020, has completed the acquisition of Kai Medical Laboratory, LLC (“KAI“) from KTM5 Holdings, LLC, NULV11, LLC and Consistent Investment Group, LLC (together, the “Vendors“), through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for consideration having an aggregate value of US$1,971,857 (CAD$2,613,478), effective as of October 5, 2020 (the “Transaction“).

COVID-19 RT-PCR TESTING IS THE GOLD STANDARD THAT ALLOWS EMPOWER TO ROLL OUT NATIONAL PHASE 4 TESTING PROGRAMS

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

“Adding Kai Medical Laboratory to the Empower Clinics family enables us to dramatically expand COVID-19 testing capability, for our get back to work & get back to school initiatives as part of our national rollout plans” said Steven McAuley, Empower’s Chairman & CEO. “Kai Medical has a newly built high-complexity lab offering a wide array of testing services, that we will leverage to serve the massive demand for national COVID testing in the U.S. Additionally, as flu season arrives and a potential second-wave of COVID takes hold, the technical infrastructure of Kai Medical allows Empower to capture testing demand and bring new technical testing products to market.”

COVID-19 TESTING PROGRAMS FOR EMPLOYERS AND DIRECT TO CONSUMER ALREADY UNDERWAY AT KAI LABORATORY

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

Finally, beyond its COVID-19 capabilities, Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals and pharmacists.

KAI MEDICAL LABORATORY TEAM LEAD BY YOSHI TYLER

The driving force behind Kai Medical Laboratory’s remarkable growth and success is Yoshi Tyler. Yoshi has a passion for being an entrepreneur, and over time, she found her true calling in healthcare. Driven by this interest, she pursued her career in the healthcare industry for more than two decades. She held leadership positions at a Fortune 500 pharmaceutical company for over thirteen years. These leadership experiences provided her with in-depth knowledge and industry insights that helped her to lead Kai Medical Laboratory towards growth.

The Kai Medical Laboratory team includes key roles including Principal Scientist, Director of Operations, Molecular Scientist, Quality Assurance, Lab Director and other critical roles.

“Kai Medical Laboratory is inspired by science and built on integrity and joining Empower allows our highly skilled personnel and state-of-the-art instrumentation to expand from a local community level to a national level” says Yoshi Tyler, Founder of Kai Medical. “Our mission is to change healthcare through science & innovative quality care, and with Empower providing an expansion of resources, Kai Medical Laboratory will be in a position to help the national need for expanded COVID-19 testing as the second wave commences.”

ADDITIONAL TERMS OF THE ACQUISITION

In connection with the closing of the Transaction (the “Closing“), Empower; (i) assumes certain short term and long term liabilities comprised of the SBA Loan of (US$1,139,577), the EIDL Loan of (US$150,000), the PPP Loan of (US$86,379), revolving debt of (US$89,478), (ii), accounts payable of (US$192,460), (iii) other short term and long term liabilities of (US$313,963), in total equal to the amount of US$1,971,857 (CAD$2,613,478), (the “Assumed Indebtedness“); the issuance of options to purchase common shares of Buyer Parent at an exercise price of CDN$0.05 per share, subject to the terms and conditions of each of the Option Agreements, in an amount equal to 400,000 share options to Yoshi Tyler, as the principal of KTM5, and 100,000 share options to Michael Haines, as the principal of NULV11 (the “Options“); and the issuance of a warrant certificate to Continuous Investment Group, LLC to purchase 500,000 common shares of Buyer Parent at a purchase price of CDN$0.05 per share, subject to the terms and conditions of the Warrant Certificate (the “Warrants“).

Market Leading Technology Kai Medical Laboratory utilizes state-of-the-art instrumentation, preeminent testing methodologies, and laboratory services enabling high-complexity accredited laboratory testing solutions, providing some of the following key instrument testing capabilities:

  • Thermo Fisher – QuantStudio 12K Flex
    • COVID-19 testing
    • Cannabis Testing
    • Clinical Genomics
  • Roche Cobas 6000
    • COVID-19 Antibody testing
    • Clinical Chemistry/Endocrinology
  • AB SCIEX 6500+ – Liquid Chromatography Mass Spectrometry
    • Clinical Chemistry/Endocrinology
    • Agriculture/Cannabis testing
  • AB SCIEX 4500 – Liquid Chromatography Mass Spectrometry
    • Urine Toxicology
    • Cannabis testing
  • SYSMEX XN-550
    • Hematology

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

(COLA) is the premier clinical laboratory accreditation, education and consultation organization. An independent accreditor whose practical, educational standards have a positive and immediate impact on patient care. http://www.cola.org

ABOUT EMPOWER

Empower is an integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT Kai Medical Laboratory

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: EMPOWER CLINICS INC.

Tags: , , , , , , , , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca Acquires Medical Laboratory Capable of Processing 4,000 #COVID-19 RT-PCR Tests Per Day $VPT.ca $ADK.ca

PyroGenesis $PYR.ca Announces Receipt of $4.8MM Down Payment under US Navy Contract $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 3:46 PM on Monday, October 5th, 2020
  • Received the first payment of approx. $4.8MM under the previously announced $11.5MM contract
  • The Contract is to provide two of PyroGenesis’ waste destruction systems, one for each ship of the US Navy’s two-ship build
  • Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81)

MONTREAL, Oct. 05, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products,  is pleased to announce that, further to its press release dated September 4th, 2020, it has received the first payment (“Down Payment”) of approx. $4.8MM under the previously announced $11.5MM contract (the “Contract”). The Contract is to provide two of PyroGenesis’ waste destruction systems (the “Systems”), one for each ship of the US Navy’s two-ship build.

The Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).

Separately, the Company expects to receive an additional $2.65MM from Drosrite International over the next few weeks.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com .

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

Tags: , , , , , ,
Posted in Featured, PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Announces Receipt of $4.8MM Down Payment under US Navy Contract $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

MEDIA: How Richard Carleton Is Leading The Cannabis Revolution At The #CSE – #Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 9:37 AM on Monday, October 5th, 2020

InnoCan Pharma (INNO:CSE) Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids. InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. Learn more.

Innocan-Blog

How Richard Carleton Is Leading The Cannabis Revolution At The CSE

Cannabis has emerged as a viable commodity for international trade, and the Canadian Stock Exchange is leading the charge.

  • A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations
  • InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes
  • This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.

The growing cannabis market

As the cannabis industry continues to advance, more and more companies are moving to get their stocks listed on Canada Securities Exchange. Cannabis is no longer just a plant. The debate on its legality, decriminalization, health benefits, among others, are now the main focus of attention. Cannabis has emerged as a viable commodity for international trade, and raw material for consumption, with several companies listed on the stock market and shareholders who speculate on its rise or fall according to news of its legalization in more corners.

A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations. InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes. This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.

Although the debate will always be present, more and more countries have chosen to decriminalize and even promote the use of cannabis, especially for medicinal purposes. The likes of Germany, Argentina, Italy, Canada, etc already allow the use of CBD derivatives to treat health problems, always under medical prescription, but often even facilitating their access to patients.

Cannabis for recreational activities is now an emerging discourse, and borders that seemed immovable a while ago have been crossed. Canada passed a regulation in 2018 that made it one of the few countries that fully allowed recreational consumption and the first of the G-8.

It thus joined Uruguay, a country that has always had a fairly permissive position. And the Netherlands, which despite the fame of its cannabis sale in coffee shops, has not changed its regulation in recent years (The Netherlands does not allow cultivation for self-consumption). As well as Mexico, who in a wide debate in recent years, have legalized marijuana for medical use. In the United States, almost 30 of its states have opened the door to medicinal consumption, and about 10 of them, including California, to recreational use.

The growth of the marijuana-related market has exploded in recent years and according to GlobeNewswire, “The global legal marijuana market size is expected to reach USD 73.6 billion by 2027.” This includes medicinal, recreational, and derivatives.

Furthermore, “It is anticipated to expand at a CAGR of 18.1% during the forecast period. The increasing legalization of cannabis for medical as well as adult-use is expected to promote growth. Based on type, the medical segment held the leading revenue share of 71% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson’s disease, and Alzheimer’s disease among other neurological conditions. Moreover, an increasing need for pain management therapies along with the growing disease burden of chronic pain among elders is expected to boost the product demand.”

In this context, in recent years numerous companies, especially in the pharmaceutical industry, have begun to fully immerse themselves in this buoyant market with the expectation that over time it will become increasingly legal in more countries. Most of these companies are Canadian, and they have emerged in the glow of the country’s decriminalization momentum.

Some are dedicated to distribution for recreational consumption, those that lean more to the medical side, and those that are specializing in derivatives. Several things unite them: they are all Canadian for their reference in legalization, they are all growing, and a lot of them have successfully been listed on the stock market.

Canadian Securities Exchange (CSE)

Without a doubt, the Canadian Securities Exchange (CSE) has played a vital role in strengthening the marijuana-related market in Canada. Led by a visionary CEO, Richard Carleton, it has emerged as one of the pillars of cannabis investment in the country. Exchange operators have critically guided affairs, bringing about the availability of a variety of investment options for cannabis investors.

The CSE is Canada’s fastest-growing stock exchange. With more than 600 listings and a cumulative market capitalization of approximately C$23 billion, the Exchange continues to attract entrepreneurial companies that are looking for the most efficient path to the North American capital markets. With the help of the Canada Securities Exchange, Canadian companies can choose to test the waters outside Canada, particularly in the United States, as long as they can allay the fears of shareholders. Presently, cannabis is illegal on a federal level in the USA, however, it is legal for medical and recreational purposes in a good number of states.

The Canadian Securities Exchange (CSE) is the go-to platform for cannabis companies who are still developing. It offers much-needed exposure for the growth of these emerging companies, while also giving established organizations, such as multi-state operators in the US, a chance to gain a competitive advantage in the global market.

According to Richard Carleton, “It is always gratifying to see companies capitalizing on opportunities in the public market to pursue their vision for growth. The CSE has a mandate to facilitate entrepreneurial activity such as this.”

Looking at the medical aspect, he further believes that large and small companies have complementary roles in the pharmaceutical industry. Start-up companies play an important role in conducting early research and development in identifying new drug therapies. History shows that a lot of value creation happens in this space before the drugs are taken through clinical trials and ultimately brought to the market by the pharma giants and are prescribed to patients worldwide. In addition, regardless of their size, pharma companies need to have exceptional technical and logistical talent to develop a drug and move it through regulated trials.

Presently, there is a tremendous amount of effort in the pursuit of therapies and vaccines for COVID-19. This recent activity is a good reminder of how powerful the public markets are at organizing capital to solve real-world issues. You can be sure that whatever health challenge society is presented with next, the market will be here to find solutions.

https://seekingalpha.com/instablog/52407514-dennz54/5504073-how-richard-carleton-is-leading-cannabis-revolution-cse

Tags: , , , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on MEDIA: How Richard Carleton Is Leading The Cannabis Revolution At The #CSE – #Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Else Nutrition Holdings Inc. $BABY.ca to Webcast Live at VirtualInvestorConfences October 8th $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 7:18 AM on Monday, October 5th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

VANCOUVER, BC / October 5, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), a developer of plant-based alternatives to dairy-based baby nutrition today announced that [Hamutal Yitzhak], [CEO], will present at VirtualInvestorConferences.com on October 8th.

DATE: Thursday, October 8th

TIME: 4:00 PM ET

LINK: https://bit.ly/3bLR2RF

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

Recent Company Highlights

  1. Recent CAD $ 25M financing and use of proceeds
  2. Recent Amazon and website launch.
  3. Current US distribution agreements and updated plans for retail rollout.
  4. H&H Global Group, company’s largest investor increased their stake in the last round of financing, and the new territories distribution and expansion plans.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access. Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For more information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director of Else Nutrition
Email: [email protected]
Telephone: 604-603-7787

Virtual Investor Conferences

John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
[email protected]

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will”, “expect” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that listing on the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tags: , , , , , , ,
Posted in Else Nutrition Holdings Inc. | Comments Off on Else Nutrition Holdings Inc. $BABY.ca to Webcast Live at VirtualInvestorConfences October 8th $KMB $BMY $ABT $WYE

PyroGenesis’ $PYR.ca CEO Files Early Warning Report; Reflects Increase in Ownership by 3.225 Million Shares $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 9:37 AM on Thursday, October 1st, 2020
  • As a result of the conversion of the Loan Mr. P. Peter Pascali, the Chief Executive Officer and President of the Company, (i) beneficially owns and controls 60,327,941 Common Shares, (ii) controls 7,251,000 Common Shares beneficially owned by 8339856 Canada Inc. (the “ Holdco ”), and (iii) controls 9,459,781 Common Shares beneficially owned by the Trust.
  • This represents, in aggregate, 77,038,722 Common Shares or slightly over 50.00% of the issued and outstanding Common Shares which are, in aggregate, 154,067,292 Common Shares

MONTREAL, Oct. 01, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, announces today that its CEO filed an early warning report. This early warning report reflects the conversion by Fiducie de Crédit Mellon Trust (the “ Trust ”) of a convertible loan of $903,000 (the “ Loan ”) into 3,225,000 common shares of the Company (“ Common Shares ”) at the request of the Company in accordance with the terms of a loan agreement between the Trust and the Company dated March 18, 2020 (the “ Loan Agreement ”). The Loan Agreement was previously disclosed by the Company in a press release issued on March 18, 2020.

As a result of the conversion of the Loan (the “ Transaction ”), Mr. P. Peter Pascali, the Chief Executive Officer and President of the Company, (i) beneficially owns and controls 60,327,941 Common Shares, (ii) controls 7,251,000 Common Shares beneficially owned by 8339856 Canada Inc. (the “ Holdco ”), and (iii) controls 9,459,781 Common Shares beneficially owned by the Trust. This represents, in aggregate, 77,038,722 Common Shares (the “ Total Ownership ”) or slightly over 50.00% of the issued and outstanding Common Shares which are, in aggregate, 154,067,292 Common Shares. The Holdco is a Canadian holding company of which Mr. P. Peter Pascali is a director, executive officer and the sole shareholder, and the Trust is a Quebec family trust of which Mr. Pascali is a trustee, executive officer and beneficiary. The Trust and the Holdco may be considered to be joint actors with Mr. Pascali.

On a fully diluted basis, assuming all options fully vest, Mr. Pascali together with Holdco and the Trust would beneficially own and control 52.19% of the issued and outstanding Common Shares of the Corporation.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com .

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

Tags: , , , , ,
Posted in All Recent Posts, PyroGenesis Canada Inc. | Comments Off on PyroGenesis’ $PYR.ca CEO Files Early Warning Report; Reflects Increase in Ownership by 3.225 Million Shares $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

PyroGenesis $PYR.ca Comments on $HPQ.ca Silicon Resources’ News Release Announcing Potential Nano Powder Pre-Order $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 2:50 PM on Wednesday, September 30th, 2020
  • HPQ announced today that it has received a request for Spherical Nano Silicon powders to be produced by the PUREVAP™ Nano Silicon Reactor (“NSiR”) from a major automobile manufacturer which, when concluded, will represent the first pre-order for these powders.
  • PyroGenesis recently entered into an agreement with HPQ Nano Silicon Powders Inc (“HPQ NANO”), a wholly owned subsidiary of HPQ in which, amongst other things,
  • PyroGenesis benefits from (i) a 10% royalty (“Royalty”) on HPQ NANO’s future sales (with set minimums), and (ii) the option to convert that Royalty at any time into a 50% ownership in HPQ NANO

MONTREAL, Sept. 30, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, comments on HPQ Silicon Resources Inc’s (“HPQ”) press release earlier today 1 announcing potential nano powder pre-order with major automobile manufacturer.

HPQ announced today that it has received a request for Spherical Nano Silicon powders to be produced by the PUREVAP™ Nano Silicon Reactor (“NSiR”) from a major automobile manufacturer which, when concluded, will represent the first pre-order for these powders.

PyroGenesis recently entered into an agreement with HPQ Nano Silicon Powders Inc (“HPQ NANO”), a wholly owned subsidiary of HPQ in which, amongst other things, PyroGenesis benefits from (i) a 10% royalty (“Royalty”) on HPQ NANO’s future sales (with set minimums), and (ii) the option to convert that Royalty at any time into a 50% ownership in HPQ NANO.

“To receive this type of validation mere weeks after signing a Development Agreement with HPQ Silicon, and mere days after a major Battery Conference, which highlighted the importance of such products, is astounding. We are excited to see HPQ NANO effectively taking pre-orders from giants in the industry who, based on our experience, are not in the habit of wasting their time,” said P. Peter Pascali, CEO and Chairman of PyroGenesis. “This validates our recent decision to increase our ownership in HPQ which we believe, in due time, will become a significant contributor to our bottom line. Although this deal has not yet been concluded and, until it is completed there are risks that it may not be, it does confirm that we are on the right path, in the right industry, with the right products, and with the right partner.”

About HPQ Silicon

HPQ Silicon Resources Inc. (TSX-V: HPQ) is a Canadian producer of Innovative Silicon Solutions, based in Montreal, building a portfolio of unique high value specialty silicon products. Working with PyroGenesis, HPQ is developing:

  • The PUREVAP™ “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which will permit the one step transformation of quartz (SiO2) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential;
  • The PUREVAP™ Nano Silicon Reactor (NSiR), a new proprietary process that can use different purities of silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires; HPQ is also working with industry leader Apollon Solar of France to use their patented process and develop a capability to produce commercially porous silicon (Si) wafers and porous silicon (Si) powders.

____________________________________
1 https://hpqsilicon.com/wp-content/uploads/2020/09/HPQ-HPQ-NANO-PRE-ORDER-SEPT-30-2020-FINAL.pdf

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com .

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President, Investors Relations and Strategic Business Development
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

Tags: , , , , , ,
Posted in Featured, PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Comments on $HPQ.ca Silicon Resources’ News Release Announcing Potential Nano Powder Pre-Order $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

« Older Entries
Newer Entries »